750 related articles for article (PubMed ID: 16982227)
41. The new pills: awaiting the next generation of oral contraceptives.
Klitsch M
Fam Plann Perspect; 1992; 24(5):226-8. PubMed ID: 1426186
[TBL] [Abstract][Full Text] [Related]
42. Rationale for new oral contraceptive dosing.
Williams JK
Int J Fertil Womens Med; 2004; 49(1):30-5. PubMed ID: 15038507
[TBL] [Abstract][Full Text] [Related]
43. Comparison of metabolic and inflammatory outcomes in women who used oral contraceptives and the levonorgestrel-releasing intrauterine device in a general population.
Morin-Papunen L; Martikainen H; McCarthy MI; Franks S; Sovio U; Hartikainen AL; Ruokonen A; Leinonen M; Laitinen J; Järvelin MR; Pouta A
Am J Obstet Gynecol; 2008 Nov; 199(5):529.e1-529.e10. PubMed ID: 18533124
[TBL] [Abstract][Full Text] [Related]
44. Venous thromboembolism in women taking hormonal contraceptives.
Blanco-Molina A; Monreal M
Expert Rev Cardiovasc Ther; 2010 Feb; 8(2):211-5. PubMed ID: 20136607
[TBL] [Abstract][Full Text] [Related]
45. Oral contraceptives and venous thromboembolism: an epidemiological review.
Lidegaard O
Eur J Contracept Reprod Health Care; 1996; 1(1):13-20. PubMed ID: 9678133
[TBL] [Abstract][Full Text] [Related]
46. Association between sex hormone-binding globulin levels and activated protein C resistance in explaining the risk of thrombosis in users of oral contraceptives containing different progestogens.
van Vliet HA; Frolich M; Christella M; Thomassen LG; Doggen CJ; Rosendaal FR; Rosing J; Helmerhorst FM
Hum Reprod; 2005 Feb; 20(2):563-8. PubMed ID: 15539435
[TBL] [Abstract][Full Text] [Related]
47. Venous thromboembolism and desogestrel- or gestodene-containing combination oral contraceptives: what are the facts?
Contracept Rep; 1996 Apr; 7(1):3-6. PubMed ID: 12320047
[TBL] [Abstract][Full Text] [Related]
48. Combined hormonal contraception and venous thromboembolism.
Martínez F; Avecilla A
Eur J Contracept Reprod Health Care; 2007 Jun; 12(2):97-106. PubMed ID: 17559006
[TBL] [Abstract][Full Text] [Related]
49. Effect of different progestagens in low oestrogen oral contraceptives on venous thromboembolic disease. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception.
Lancet; 1995 Dec; 346(8990):1582-8. PubMed ID: 7500749
[TBL] [Abstract][Full Text] [Related]
50. Modeled estimates of myocardial infarction and venous thromboembolic disease in users of second and third generation oral contraceptives.
Schwingl PJ; Shelton J
Contraception; 1997 Mar; 55(3):125-9. PubMed ID: 9114999
[TBL] [Abstract][Full Text] [Related]
51. A perspective on the concept of "risk".
Westhoff CL
Dialogues Contracept; 1996; 5(1):8-9. PubMed ID: 12347723
[TBL] [Abstract][Full Text] [Related]
52. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
Brenner P
Contraception; 2006 Oct; 74(4):354; author reply 354-5. PubMed ID: 16982246
[No Abstract] [Full Text] [Related]
53. Comparison of a transdermal contraceptive patch vs. oral contraceptives on hemostasis variables.
Kluft C; Meijer P; LaGuardia KD; Fisher AC
Contraception; 2008 Feb; 77(2):77-83. PubMed ID: 18226669
[TBL] [Abstract][Full Text] [Related]
54. Effects on hemostatic variables of desogestrel- and gestodene-containing oral contraceptives in comparison with levonorgestrel-containing oral contraceptives: a review.
Winkler UH
Am J Obstet Gynecol; 1998 Sep; 179(3 Pt 2):S51-61. PubMed ID: 9753311
[TBL] [Abstract][Full Text] [Related]
55. Comparative effects of combined oral contraceptives containing desogestrel or levonorgestrel on serum lipids, lipoproteins and sex hormone binding globulin in healthy women.
Sirimongkolkasem R; Rojanasakul A; Phiromsawat S; Chailurkit L
J Med Assoc Thai; 1988 Jul; 71 Suppl 2():68-73. PubMed ID: 2972791
[TBL] [Abstract][Full Text] [Related]
56. Recent combined hormonal contraceptives (CHCs) and the risk of thromboembolism and other cardiovascular events in new users.
Sidney S; Cheetham TC; Connell FA; Ouellet-Hellstrom R; Graham DJ; Davis D; Sorel M; Quesenberry CP; Cooper WO
Contraception; 2013 Jan; 87(1):93-100. PubMed ID: 23083525
[TBL] [Abstract][Full Text] [Related]
57. Effects of the contraceptive patch, the vaginal ring and an oral contraceptive on APC resistance and SHBG: a cross-over study.
Fleischer K; van Vliet HA; Rosendaal FR; Rosing J; Tchaikovski S; Helmerhorst FM
Thromb Res; 2009; 123(3):429-35. PubMed ID: 18829069
[TBL] [Abstract][Full Text] [Related]
58. Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial.
Johnson JV; Lowell J; Badger GJ; Rosing J; Tchaikovski S; Cushman M
Obstet Gynecol; 2008 Feb; 111(2 Pt 1):278-84. PubMed ID: 18238963
[TBL] [Abstract][Full Text] [Related]
59. Prolonged use of the etonogestrel implant and levonorgestrel intrauterine device: 2 years beyond Food and Drug Administration-approved duration.
McNicholas C; Swor E; Wan L; Peipert JF
Am J Obstet Gynecol; 2017 Jun; 216(6):586.e1-586.e6. PubMed ID: 28147241
[TBL] [Abstract][Full Text] [Related]
60. Adolescents' experiences using the contraceptive patch versus pills.
Sucato GS; Land SR; Murray PJ; Cecchini R; Gold MA
J Pediatr Adolesc Gynecol; 2011 Aug; 24(4):197-203. PubMed ID: 21454110
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
